Drug Profile
Andes 1537
Alternative Names: Andes-1537Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Andes Biotechnologies
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Chile (SC, Injection)
- 17 Feb 2022 Andes Biotechnologies completed a phase-I clinical trial in Solid tumours (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable,) in Chile (SC) (NCT03985072)
- 26 Apr 2019 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable,) in Chile (SC) (NCT03985072)